Latest Content

Agreement supports commercialization and reimbursement efforts for tobevibart plus elebsiran as the ECLIPSE clinical program advances, including completion of enrollment for the ECLIPSE 3 trial.

The single-source award will fund a large randomized trial evaluating mortality, morbidity, and developmental outcomes following the hepatitis B birth dose, amid ongoing debate over non-specific vaccine effects.

This week, learn more about Emory's approach around treating high-consequence infectious diseases such as Ebola, a UNC researcher's work in sequencing syphilis genomes in the search to develop a global vaccine, how the US is in danger of losing its elimination status for measles, and more.

Emory's Gavin Harris, MD, talks about taking care of patients with high-consequence infectious diseases, and considerations for not only their care, but their families. He also discusses working with other healthcare facilities around COVID-19 care and educating them through Emory's ECHO program on new and existing threats.

Zandraetta Tims-Cook, MD, MPH, AAHIVS, discusses access challenges, missed-dose management, and scalable care models for cabotegravir PrEP in women.

CDC reports over 1,900 confirmed cases and 49 outbreaks nationwide, with recent surges reported in South Carolina, Utah, Arizona, and Connecticut amid declining childhood vaccination coverage.

Jonathan Parr, MD, MPH, discusses his work in locating potential targets to develop a syphilis vaccine and the challenges associated with genomic diversity of subpopulations of the main pathogen, Treponema pallidum.

A Nature Microbiology study shows that structure-guided bile acid design can lock Clostridioides difficile toxin B into an inactive conformation, protecting mice from disease without disrupting the gut microbiome.

This new recommendation relates to infants born to women who test negative for hepatitis B. This is a departure from the federal agency’s previous recommendation and comes on the heels of the ACIP’s recent meeting.

An impending deadline is coming up in early 2026 that could cause the country to lose its status. However, this can be reversible and unnecessary infections, severe disease, and deaths can be avoided. Rodney Rohde, PhD, talks about incidence rates, how we got here, and strategies to increase immunizations.

Margaret Aldrich, MD, provides insight around this concept, addressing stewardship within this patient population, and how their institution’s collaborative work environment helps all of the department’s clinicians.

Gilead Sciences reported positive phase 3 ARTISTRY-2 results demonstrating that a once-daily single-tablet combination of bictegravir and lenacapavir is statistically noninferior to bictegravir/emtricitabine/tenofovir alafenamide tablets in virologically suppressed adults with HIV. The company plans to file for regulatory submissions for approval.

With a novel, non–cross-resistant mechanism and phase 3 data showing noninferior efficacy to injectable standard therapy, zoliflodacin could become a novel treatment that expands clinician choice and strengthens global efforts to combat antimicrobial-resistant gonorrhea. Innoviva CMO David Altarac, MD, offers further insights about the newly-approved antibiotic and its potential place in the market.